SlideShare a Scribd company logo
1 of 20
Download to read offline
Barclays Capital
Global Healthcare Conference




                   March 10, 2009
Who is Quest Diagnostics?
•Leader in Providing Healthcare Insights and Solutions
• Comprehensive Diagnostic Testing
    • Routine ——» Esoteric
           Diagnose
       •
           Monitor
       •
           Predict
       •
           Prevent
       •
–Advanced Information Technology Solutions
    • Improve Care and Efficiency
–Facilitate Introduction of New Therapeutics
    • Clinical Trials Testing
–Innovative Diagnostic Products
    • Enable Care Closer to the Patient
–Risk Assessment Solutions to Life Insurance Industry

 Touching Patients 150 Million Times Each Year
                                                        Patients | Growth | People
History of Strong Growth




                                                        20%
                                                   Revenue 1999-2008
                                                   10-year CAGR 20%




                                                        27%
                                                    EPS* 1999-2008
                                                   10-year CAGR 27%




$ in billions except EPS
                                                      Patients | Growth | People
*EPS is from continuing operations
Favorable Industry Trends

Essential Healthcare Service

 • Growing and Aging Population

 • Scientific & Medical Innovations

 • Personal Interest in Health

 • Convergence of Information


Influences >70% of Healthcare Decisions
                                          Patients | Growth | People
Moving to Higher Growth,
                       Higher Margin Testing Segments

     2000 Revenue                       2008 Revenue




Total Revenue: $3.4 Billion         Total Revenue: $7.2 Billion


                                                       Patients | Growth | People
Expanding Market Leadership
                                                              2009
                                                 2000
• Clinical Testing                           •            •
• Gene-based & Esoteric Testing              •            •
• Employer Services                          •            •
• Anatomic Pathology Testing                 •P           •
• Risk Assessment Services                   •-           •
• Healthcare Information Technology          •-           •
• Point of Care (Near Patient) Testing       •-           •
• Clinical Trials Testing                    •P           •P
• International Market                       •-           •P

    Overall Market Leader/Niche Leadership
  P Market Participant                                  Patients | Growth | People
Our Longer Term Goals

•Undisputed World Leader in Diagnostic Testing,
 Information and Services

•Profitably Grow > Industry Rate

•Expand Operating Income to 20% of Revenues

•Expand International Operations to ~10% of Revenues




                                              Patients | Growth | People
Strategy to Drive Profitable Growth

Leverage Capabilities To Create Differentiation

    Deliver Superior Patient Experience
    Continuously Drive Six Sigma Quality
    Lead in Medical Innovation
    Leverage Unparalleled Assets & Capabilities
    Expand Diagnostic Scope
    Expand Geographic Reach

Sustainable Competitive Advantage                 Patients | Growth | People
Delivering Superior Patient Experience

Patient Gold Standards
Prompt, caring, courteous service


PSC Appointment Scheduling
First laboratory with PSC appointment scheduling
Reduces patient wait time; improves convenience


Google Health Collaboration
Facilitate patient-physician communications
Secure electronic access to lab results
                                                   Patients | Growth | People
Leading Medical Innovator

Multiple Channels to Access New Technology
   Internal Development – Nichols Institute
   Joint Development Relationships
   Licensing/Distribution Relationships
Focused on Addressing Areas of Significant Patient Need
   Cancer, Cardiovascular Conditions, Infectious Disease
   Less invasive; less painful; more convenient for patients
Leading Experts for Medical Consultation
   900 MDs & PhDs
Culture of Collaborative Innovation
   Academic relationships
   Investment in innovative firms and technologies
   Partnerships with pharmaceutical companies
                                                        Patients | Growth | People
Continual Stream of
                                  Diagnostic Testing Advances
Cancer                                Transplantation/Coagulation
   LeumetaTM                             HLA FDA-registered lab
   HE-4                                  Coag consultations
   H/I Breast Recurrence           New Technologies/New Applications
   Cancer of Unknown Primary
                                      XSenseTM (Fragile X)
   Septin 9 Colorectal Cancer Test
                                      ClarisureTM (CGH Microarray)
Cardiovascular Disease
                                         LC/MS for Amino Acids
   Ion Mobility (Lipid Profile)
                                         LC-MS/MS
Infectious Disease
   HepaScoreTM
   Chikungunya
                                                              Patients | Growth | People
   Italics – under development
Personalized and Targeted Medicine
                      is an Emerging Opportunity
Enables More Appropriate Drug Therapy
   Rituxan®         Rituxan® Sensitivity (CD20)
   Herceptin®       Her2
   Campath®         Campath Sensitivity (CD2)
   Irinotecan       UGT1A1
   Erbitux®         RAS
   Warfarin         CYP450 2C9
   Carbamazephine   HLA - screens out certain Asian patients
   Abacavir         HLA - predisposition to hypersensitivity
   Aspirin          Monitor personal resistance levels
Improves Disease Management
   Leumeta™         CellSearch
   Hepascore™
Improving Patient Care …..Reducing Medical Costs
                                                    Patients | Growth | People
Unparalleled Assets and Capabilities
     Serving 50% of US Hospitals & Physicians
        2,300 Patient Service Centers and Laboratories
        900 MD’s and PhD’s
        8,500 Phlebotomists &
          5,000 Paramedical professionals
        3,500 Courier Vehicles and 25 Airplanes
          - making 90,000 stops each day
        >140,000 Physician users of Care360
        POC testing in >100 Countries

Testing ~1,000,000 Patients a Day through our Labs and POC Devices
                                                     Patients | Growth | People
Expanding Diagnostic Scope
                                   Near Patient Testing

Opportunity to Improve Patient Care

 Attractive benefits for hospitals,
 physician offices, rural and
 international markets
 Enables more timely and
 effective decisions
 Expanding product menu
 Platform technology
 Results integrated into Care360

Reducing Medical Costs
                                               Patients | Growth | People
Expanding Geographic Reach

Broadening Our Geographical Coverage

  Clear leadership in U.S….with room to grow

  Leverage existing labs in Puerto Rico, Mexico, and UK

  Providing cervical cancer screening for Ireland NHS

  Increase foreign testing sent to Nichols Institute

  Entered India – serving multiple markets

Increasing Market Opportunity
                                                   Patients | Growth | People
On Track to Reduce Costs by $500 Million

Leverage Lean Six Sigma to Improve Efficiency
 Streamline Lab Operations

 Optimize Logistics Routes
 and PSC Resources

 Improve Billing and Call
 Center Operations

 Leverage Purchasing
 Capabilities

 $300 million savings run rate exiting 2008
Maintain Service Levels & Stimulate Growth
                                              Patients | Growth | People
2008 Results

Strong Growth in Revenue, Earnings and Cash Flow


                              $7.2 B, ↑ 8.1%
Revenues

                              16.9%, ↑ 0.6%
Operating Income

                                       ↑14%
EPS                           $3.23,

Cash from Operations          $1.1 Billion



                                             Patients | Growth | People
2009 Guidance

Continued Revenue & Earnings Growth
                                                         ↑ ~3%
Revenues

Operating Income %                                       approaching 18%

                                                         $3.50 - $3.70, ↑ 8% - 15%
EPS

Cash from Operations *                                   ~$1 billion

CapEx                                                    ~$200 million

Strenghening our Leadership Position
*Excludes expected payment of the $316 million reserve
                                                                         Patients | Growth | People
established for the previously disclosed NID matter
Building on Strength

Leader in a vital and growing industry

Uniquely positioned with unparalleled assets & capabilities

History of disciplined growth and successful acquisitions

Strong cash generator, with a strong balance sheet

Proven management team



Focused on Execution
                                                Patients | Growth | People
Patients | Growth | People

More Related Content

What's hot

quest diagnostics 2000annualreport
quest diagnostics 2000annualreportquest diagnostics 2000annualreport
quest diagnostics 2000annualreport
finance34
 
Group4_Week10_Final_Business_Plan_VERSION_8(1)
Group4_Week10_Final_Business_Plan_VERSION_8(1)Group4_Week10_Final_Business_Plan_VERSION_8(1)
Group4_Week10_Final_Business_Plan_VERSION_8(1)
roxiefoxx
 
Datamonitor Consulting: Opportunity Assessment and Forecasting in the Pharmac...
Datamonitor Consulting: Opportunity Assessment and Forecasting in the Pharmac...Datamonitor Consulting: Opportunity Assessment and Forecasting in the Pharmac...
Datamonitor Consulting: Opportunity Assessment and Forecasting in the Pharmac...
Datamonitor Consulting
 
(Final Presentation) CodeVantage Code Halo System UMD 2015
(Final Presentation) CodeVantage Code Halo System UMD 2015(Final Presentation) CodeVantage Code Halo System UMD 2015
(Final Presentation) CodeVantage Code Halo System UMD 2015
Bill Fegan, MBA, PMP
 

What's hot (13)

Ir day final_517
Ir day final_517Ir day final_517
Ir day final_517
 
Nhc corporate presentation july 12, 2016
Nhc corporate presentation july 12, 2016Nhc corporate presentation july 12, 2016
Nhc corporate presentation july 12, 2016
 
Nhc corporate presentation july 12, 2016
Nhc corporate presentation july 12, 2016Nhc corporate presentation july 12, 2016
Nhc corporate presentation july 12, 2016
 
quest diagnostics 2000annualreport
quest diagnostics 2000annualreportquest diagnostics 2000annualreport
quest diagnostics 2000annualreport
 
Service improvement for radiologists
Service improvement for radiologistsService improvement for radiologists
Service improvement for radiologists
 
Group4_Week10_Final_Business_Plan_VERSION_8(1)
Group4_Week10_Final_Business_Plan_VERSION_8(1)Group4_Week10_Final_Business_Plan_VERSION_8(1)
Group4_Week10_Final_Business_Plan_VERSION_8(1)
 
Nobilis corp pres 09.17 cantor fitzgerald conference
Nobilis corp pres 09.17 cantor fitzgerald conference Nobilis corp pres 09.17 cantor fitzgerald conference
Nobilis corp pres 09.17 cantor fitzgerald conference
 
Cantor 2017 HC Conference
Cantor 2017 HC Conference Cantor 2017 HC Conference
Cantor 2017 HC Conference
 
Kurk Medical
Kurk MedicalKurk Medical
Kurk Medical
 
Nvta cowen 2018 final
Nvta cowen 2018 finalNvta cowen 2018 final
Nvta cowen 2018 final
 
Datamonitor Consulting: Opportunity Assessment and Forecasting in the Pharmac...
Datamonitor Consulting: Opportunity Assessment and Forecasting in the Pharmac...Datamonitor Consulting: Opportunity Assessment and Forecasting in the Pharmac...
Datamonitor Consulting: Opportunity Assessment and Forecasting in the Pharmac...
 
Top 10 IVD Companies
Top 10 IVD CompaniesTop 10 IVD Companies
Top 10 IVD Companies
 
(Final Presentation) CodeVantage Code Halo System UMD 2015
(Final Presentation) CodeVantage Code Halo System UMD 2015(Final Presentation) CodeVantage Code Halo System UMD 2015
(Final Presentation) CodeVantage Code Halo System UMD 2015
 

Viewers also liked

quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08
finance34
 
quest diagnostics 03 09GovernanceCommitteeCharter
quest diagnostics 03 09GovernanceCommitteeCharterquest diagnostics 03 09GovernanceCommitteeCharter
quest diagnostics 03 09GovernanceCommitteeCharter
finance34
 
AMD annual-1999
AMD annual-1999AMD annual-1999
AMD annual-1999
finance34
 
WESCO AR 2007
WESCO AR 2007WESCO AR 2007
WESCO AR 2007
finance34
 
quest diagnostics Incorp
quest diagnostics Incorpquest diagnostics Incorp
quest diagnostics Incorp
finance34
 
quest diagnostics Q308_Transcript
quest diagnostics Q308_Transcriptquest diagnostics Q308_Transcript
quest diagnostics Q308_Transcript
finance34
 

Viewers also liked (6)

quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08
 
quest diagnostics 03 09GovernanceCommitteeCharter
quest diagnostics 03 09GovernanceCommitteeCharterquest diagnostics 03 09GovernanceCommitteeCharter
quest diagnostics 03 09GovernanceCommitteeCharter
 
AMD annual-1999
AMD annual-1999AMD annual-1999
AMD annual-1999
 
WESCO AR 2007
WESCO AR 2007WESCO AR 2007
WESCO AR 2007
 
quest diagnostics Incorp
quest diagnostics Incorpquest diagnostics Incorp
quest diagnostics Incorp
 
quest diagnostics Q308_Transcript
quest diagnostics Q308_Transcriptquest diagnostics Q308_Transcript
quest diagnostics Q308_Transcript
 

Similar to quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3.10.09

quest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCCquest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCC
finance34
 
quest diagnostics Jefferies_Conf_6_24_08
quest diagnostics Jefferies_Conf_6_24_08quest diagnostics Jefferies_Conf_6_24_08
quest diagnostics Jefferies_Conf_6_24_08
finance34
 
quest diagnostics 6_25Jefferies6_26_07
quest diagnostics 6_25Jefferies6_26_07quest diagnostics 6_25Jefferies6_26_07
quest diagnostics 6_25Jefferies6_26_07
finance34
 
quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07
finance34
 
quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07
finance34
 
quest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenquest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowen
finance34
 
quest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenquest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowen
finance34
 
SCIE Investor Presentation January 2017
SCIE Investor Presentation January 2017SCIE Investor Presentation January 2017
SCIE Investor Presentation January 2017
Mike Oliver
 
bristol myerd squibb Merrill Lynch Global Pharmaceutical, Biotechnology & Med...
bristol myerd squibb Merrill Lynch Global Pharmaceutical, Biotechnology & Med...bristol myerd squibb Merrill Lynch Global Pharmaceutical, Biotechnology & Med...
bristol myerd squibb Merrill Lynch Global Pharmaceutical, Biotechnology & Med...
finance13
 

Similar to quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3.10.09 (20)

quest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCCquest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCC
 
quest diagnostics Jefferies_Conf_6_24_08
quest diagnostics Jefferies_Conf_6_24_08quest diagnostics Jefferies_Conf_6_24_08
quest diagnostics Jefferies_Conf_6_24_08
 
quest diagnostics 6_25Jefferies6_26_07
quest diagnostics 6_25Jefferies6_26_07quest diagnostics 6_25Jefferies6_26_07
quest diagnostics 6_25Jefferies6_26_07
 
quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07
 
quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07
 
quest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenquest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowen
 
quest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenquest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowen
 
Cgix
CgixCgix
Cgix
 
SCIE Investor Presentation January 2017
SCIE Investor Presentation January 2017SCIE Investor Presentation January 2017
SCIE Investor Presentation January 2017
 
NeoGenomics Laboratory Company Overview Presentation 01/20/2014
NeoGenomics Laboratory Company Overview Presentation 01/20/2014NeoGenomics Laboratory Company Overview Presentation 01/20/2014
NeoGenomics Laboratory Company Overview Presentation 01/20/2014
 
NeoGenomics Laboratory Company Overview Presentation 01/09/2014
NeoGenomics Laboratory Company Overview Presentation 01/09/2014NeoGenomics Laboratory Company Overview Presentation 01/09/2014
NeoGenomics Laboratory Company Overview Presentation 01/09/2014
 
NGNM Company Overview Presentation July 2013
NGNM Company Overview Presentation July 2013NGNM Company Overview Presentation July 2013
NGNM Company Overview Presentation July 2013
 
2013 12 04 neo company overview presentation
2013 12 04   neo company overview presentation2013 12 04   neo company overview presentation
2013 12 04 neo company overview presentation
 
NeoGenomics Company Overview Presentation 12/04/2013
NeoGenomics Company Overview Presentation 12/04/2013NeoGenomics Company Overview Presentation 12/04/2013
NeoGenomics Company Overview Presentation 12/04/2013
 
NeoGenomics Company Overview Presentation 2013
NeoGenomics Company Overview Presentation 2013NeoGenomics Company Overview Presentation 2013
NeoGenomics Company Overview Presentation 2013
 
NeoGenomics Company Overview Presentation 2013_10_23
NeoGenomics Company Overview Presentation 2013_10_23 NeoGenomics Company Overview Presentation 2013_10_23
NeoGenomics Company Overview Presentation 2013_10_23
 
NGNM Company Overview Presentation Aug 2013
NGNM Company Overview Presentation Aug 2013NGNM Company Overview Presentation Aug 2013
NGNM Company Overview Presentation Aug 2013
 
2014 03 11 neo company overview presentation
2014 03 11   neo company overview presentation2014 03 11   neo company overview presentation
2014 03 11 neo company overview presentation
 
NeoGenomics Laboratory Company Overview 2014-03-11
NeoGenomics Laboratory Company Overview 2014-03-11 NeoGenomics Laboratory Company Overview 2014-03-11
NeoGenomics Laboratory Company Overview 2014-03-11
 
bristol myerd squibb Merrill Lynch Global Pharmaceutical, Biotechnology & Med...
bristol myerd squibb Merrill Lynch Global Pharmaceutical, Biotechnology & Med...bristol myerd squibb Merrill Lynch Global Pharmaceutical, Biotechnology & Med...
bristol myerd squibb Merrill Lynch Global Pharmaceutical, Biotechnology & Med...
 

More from finance34

charter communications 1Qslides_FINAL
charter communications 1Qslides_FINALcharter communications 1Qslides_FINAL
charter communications 1Qslides_FINAL
finance34
 
charter communications 1Qslides_FINAL
charter communications 1Qslides_FINALcharter communications 1Qslides_FINAL
charter communications 1Qslides_FINAL
finance34
 
charter communications 2Q07_Slides
charter communications 2Q07_Slidescharter communications 2Q07_Slides
charter communications 2Q07_Slides
finance34
 
charter communications 2Q07_Slides
charter communications 2Q07_Slidescharter communications 2Q07_Slides
charter communications 2Q07_Slides
finance34
 
charter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALcharter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINAL
finance34
 
charter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALcharter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINAL
finance34
 
charter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationcharter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentation
finance34
 
charter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationcharter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentation
finance34
 
charter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALcharter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINAL
finance34
 
charter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALcharter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINAL
finance34
 
charter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALcharter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINAL
finance34
 
charter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALcharter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINAL
finance34
 
charter communications proxy00
charter communications proxy00charter communications proxy00
charter communications proxy00
finance34
 
charter communications proxy00
charter communications proxy00charter communications proxy00
charter communications proxy00
finance34
 
CHRT_000502__154_120
CHRT_000502__154_120CHRT_000502__154_120
CHRT_000502__154_120
finance34
 
CHRT_000502__154_120
CHRT_000502__154_120CHRT_000502__154_120
CHRT_000502__154_120
finance34
 
charter communications ar_00
charter communications ar_00charter communications ar_00
charter communications ar_00
finance34
 
charter communications ar_00
charter communications ar_00charter communications ar_00
charter communications ar_00
finance34
 

More from finance34 (20)

charter communications 1Qslides_FINAL
charter communications 1Qslides_FINALcharter communications 1Qslides_FINAL
charter communications 1Qslides_FINAL
 
charter communications 1Qslides_FINAL
charter communications 1Qslides_FINALcharter communications 1Qslides_FINAL
charter communications 1Qslides_FINAL
 
charter communications 2Q07_Slides
charter communications 2Q07_Slidescharter communications 2Q07_Slides
charter communications 2Q07_Slides
 
charter communications 2Q07_Slides
charter communications 2Q07_Slidescharter communications 2Q07_Slides
charter communications 2Q07_Slides
 
charter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALcharter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINAL
 
charter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALcharter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINAL
 
charter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationcharter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentation
 
charter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationcharter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentation
 
charter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALcharter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINAL
 
charter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALcharter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINAL
 
charter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALcharter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINAL
 
charter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALcharter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINAL
 
charter communications proxy00
charter communications proxy00charter communications proxy00
charter communications proxy00
 
charter communications proxy00
charter communications proxy00charter communications proxy00
charter communications proxy00
 
CHRT_000502__154_120
CHRT_000502__154_120CHRT_000502__154_120
CHRT_000502__154_120
 
CHRT_000502__154_120
CHRT_000502__154_120CHRT_000502__154_120
CHRT_000502__154_120
 
chtr_010502
chtr_010502chtr_010502
chtr_010502
 
chtr_010502
chtr_010502chtr_010502
chtr_010502
 
charter communications ar_00
charter communications ar_00charter communications ar_00
charter communications ar_00
 
charter communications ar_00
charter communications ar_00charter communications ar_00
charter communications ar_00
 

Recently uploaded

Call Girls in Yamuna Vihar (delhi) call me [🔝9953056974🔝] escort service 24X7
Call Girls in  Yamuna Vihar  (delhi) call me [🔝9953056974🔝] escort service 24X7Call Girls in  Yamuna Vihar  (delhi) call me [🔝9953056974🔝] escort service 24X7
Call Girls in Yamuna Vihar (delhi) call me [🔝9953056974🔝] escort service 24X7
9953056974 Low Rate Call Girls In Saket, Delhi NCR
 
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdfMASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
Cocity Enterprises
 
Call Girls in Tilak Nagar (delhi) call me [🔝9953056974🔝] escort service 24X7
Call Girls in Tilak Nagar (delhi) call me [🔝9953056974🔝] escort service 24X7Call Girls in Tilak Nagar (delhi) call me [🔝9953056974🔝] escort service 24X7
Call Girls in Tilak Nagar (delhi) call me [🔝9953056974🔝] escort service 24X7
9953056974 Low Rate Call Girls In Saket, Delhi NCR
 

Recently uploaded (20)

Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budgetCall Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
 
Seeman_Fiintouch_LLP_Newsletter_May-2024.pdf
Seeman_Fiintouch_LLP_Newsletter_May-2024.pdfSeeman_Fiintouch_LLP_Newsletter_May-2024.pdf
Seeman_Fiintouch_LLP_Newsletter_May-2024.pdf
 
Significant AI Trends for the Financial Industry in 2024 and How to Utilize Them
Significant AI Trends for the Financial Industry in 2024 and How to Utilize ThemSignificant AI Trends for the Financial Industry in 2024 and How to Utilize Them
Significant AI Trends for the Financial Industry in 2024 and How to Utilize Them
 
Female Russian Escorts Mumbai Call Girls-((ANdheri))9833754194-Jogeshawri Fre...
Female Russian Escorts Mumbai Call Girls-((ANdheri))9833754194-Jogeshawri Fre...Female Russian Escorts Mumbai Call Girls-((ANdheri))9833754194-Jogeshawri Fre...
Female Russian Escorts Mumbai Call Girls-((ANdheri))9833754194-Jogeshawri Fre...
 
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
 
Technology industry / Finnish economic outlook
Technology industry / Finnish economic outlookTechnology industry / Finnish economic outlook
Technology industry / Finnish economic outlook
 
Famous No1 Amil Baba Love marriage Astrologer Specialist Expert In Pakistan a...
Famous No1 Amil Baba Love marriage Astrologer Specialist Expert In Pakistan a...Famous No1 Amil Baba Love marriage Astrologer Specialist Expert In Pakistan a...
Famous No1 Amil Baba Love marriage Astrologer Specialist Expert In Pakistan a...
 
Call Girls in Yamuna Vihar (delhi) call me [🔝9953056974🔝] escort service 24X7
Call Girls in  Yamuna Vihar  (delhi) call me [🔝9953056974🔝] escort service 24X7Call Girls in  Yamuna Vihar  (delhi) call me [🔝9953056974🔝] escort service 24X7
Call Girls in Yamuna Vihar (delhi) call me [🔝9953056974🔝] escort service 24X7
 
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdfMASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
 
Virar Best Sex Call Girls Number-📞📞9833754194-Poorbi Nalasopara Housewife Cal...
Virar Best Sex Call Girls Number-📞📞9833754194-Poorbi Nalasopara Housewife Cal...Virar Best Sex Call Girls Number-📞📞9833754194-Poorbi Nalasopara Housewife Cal...
Virar Best Sex Call Girls Number-📞📞9833754194-Poorbi Nalasopara Housewife Cal...
 
Dubai Call Girls Deira O525547819 Dubai Call Girls Bur Dubai Multiple
Dubai Call Girls Deira O525547819 Dubai Call Girls Bur Dubai MultipleDubai Call Girls Deira O525547819 Dubai Call Girls Bur Dubai Multiple
Dubai Call Girls Deira O525547819 Dubai Call Girls Bur Dubai Multiple
 
Business Principles, Tools, and Techniques in Participating in Various Types...
Business Principles, Tools, and Techniques  in Participating in Various Types...Business Principles, Tools, and Techniques  in Participating in Various Types...
Business Principles, Tools, and Techniques in Participating in Various Types...
 
Pension dashboards forum 1 May 2024 (1).pdf
Pension dashboards forum 1 May 2024 (1).pdfPension dashboards forum 1 May 2024 (1).pdf
Pension dashboards forum 1 May 2024 (1).pdf
 
logistics industry development power point ppt.pdf
logistics industry development power point ppt.pdflogistics industry development power point ppt.pdf
logistics industry development power point ppt.pdf
 
Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...
Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...
Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...
 
7 steps to achieve financial freedom.pdf
7 steps to achieve financial freedom.pdf7 steps to achieve financial freedom.pdf
7 steps to achieve financial freedom.pdf
 
Benefits & Risk Of Stock Loans
Benefits & Risk Of Stock LoansBenefits & Risk Of Stock Loans
Benefits & Risk Of Stock Loans
 
Call Girls in Tilak Nagar (delhi) call me [🔝9953056974🔝] escort service 24X7
Call Girls in Tilak Nagar (delhi) call me [🔝9953056974🔝] escort service 24X7Call Girls in Tilak Nagar (delhi) call me [🔝9953056974🔝] escort service 24X7
Call Girls in Tilak Nagar (delhi) call me [🔝9953056974🔝] escort service 24X7
 
Test bank for advanced assessment interpreting findings and formulating diffe...
Test bank for advanced assessment interpreting findings and formulating diffe...Test bank for advanced assessment interpreting findings and formulating diffe...
Test bank for advanced assessment interpreting findings and formulating diffe...
 
Bhubaneswar🌹Ravi Tailkes ❤CALL GIRLS 9777949614 💟 CALL GIRLS IN bhubaneswar ...
Bhubaneswar🌹Ravi Tailkes  ❤CALL GIRLS 9777949614 💟 CALL GIRLS IN bhubaneswar ...Bhubaneswar🌹Ravi Tailkes  ❤CALL GIRLS 9777949614 💟 CALL GIRLS IN bhubaneswar ...
Bhubaneswar🌹Ravi Tailkes ❤CALL GIRLS 9777949614 💟 CALL GIRLS IN bhubaneswar ...
 

quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3.10.09

  • 1. Barclays Capital Global Healthcare Conference March 10, 2009
  • 2. Who is Quest Diagnostics? •Leader in Providing Healthcare Insights and Solutions • Comprehensive Diagnostic Testing • Routine ——» Esoteric Diagnose • Monitor • Predict • Prevent • –Advanced Information Technology Solutions • Improve Care and Efficiency –Facilitate Introduction of New Therapeutics • Clinical Trials Testing –Innovative Diagnostic Products • Enable Care Closer to the Patient –Risk Assessment Solutions to Life Insurance Industry Touching Patients 150 Million Times Each Year Patients | Growth | People
  • 3. History of Strong Growth 20% Revenue 1999-2008 10-year CAGR 20% 27% EPS* 1999-2008 10-year CAGR 27% $ in billions except EPS Patients | Growth | People *EPS is from continuing operations
  • 4. Favorable Industry Trends Essential Healthcare Service • Growing and Aging Population • Scientific & Medical Innovations • Personal Interest in Health • Convergence of Information Influences >70% of Healthcare Decisions Patients | Growth | People
  • 5. Moving to Higher Growth, Higher Margin Testing Segments 2000 Revenue 2008 Revenue Total Revenue: $3.4 Billion Total Revenue: $7.2 Billion Patients | Growth | People
  • 6. Expanding Market Leadership 2009 2000 • Clinical Testing • • • Gene-based & Esoteric Testing • • • Employer Services • • • Anatomic Pathology Testing •P • • Risk Assessment Services •- • • Healthcare Information Technology •- • • Point of Care (Near Patient) Testing •- • • Clinical Trials Testing •P •P • International Market •- •P Overall Market Leader/Niche Leadership P Market Participant Patients | Growth | People
  • 7. Our Longer Term Goals •Undisputed World Leader in Diagnostic Testing, Information and Services •Profitably Grow > Industry Rate •Expand Operating Income to 20% of Revenues •Expand International Operations to ~10% of Revenues Patients | Growth | People
  • 8. Strategy to Drive Profitable Growth Leverage Capabilities To Create Differentiation Deliver Superior Patient Experience Continuously Drive Six Sigma Quality Lead in Medical Innovation Leverage Unparalleled Assets & Capabilities Expand Diagnostic Scope Expand Geographic Reach Sustainable Competitive Advantage Patients | Growth | People
  • 9. Delivering Superior Patient Experience Patient Gold Standards Prompt, caring, courteous service PSC Appointment Scheduling First laboratory with PSC appointment scheduling Reduces patient wait time; improves convenience Google Health Collaboration Facilitate patient-physician communications Secure electronic access to lab results Patients | Growth | People
  • 10. Leading Medical Innovator Multiple Channels to Access New Technology Internal Development – Nichols Institute Joint Development Relationships Licensing/Distribution Relationships Focused on Addressing Areas of Significant Patient Need Cancer, Cardiovascular Conditions, Infectious Disease Less invasive; less painful; more convenient for patients Leading Experts for Medical Consultation 900 MDs & PhDs Culture of Collaborative Innovation Academic relationships Investment in innovative firms and technologies Partnerships with pharmaceutical companies Patients | Growth | People
  • 11. Continual Stream of Diagnostic Testing Advances Cancer Transplantation/Coagulation LeumetaTM HLA FDA-registered lab HE-4 Coag consultations H/I Breast Recurrence New Technologies/New Applications Cancer of Unknown Primary XSenseTM (Fragile X) Septin 9 Colorectal Cancer Test ClarisureTM (CGH Microarray) Cardiovascular Disease LC/MS for Amino Acids Ion Mobility (Lipid Profile) LC-MS/MS Infectious Disease HepaScoreTM Chikungunya Patients | Growth | People Italics – under development
  • 12. Personalized and Targeted Medicine is an Emerging Opportunity Enables More Appropriate Drug Therapy Rituxan® Rituxan® Sensitivity (CD20) Herceptin® Her2 Campath® Campath Sensitivity (CD2) Irinotecan UGT1A1 Erbitux® RAS Warfarin CYP450 2C9 Carbamazephine HLA - screens out certain Asian patients Abacavir HLA - predisposition to hypersensitivity Aspirin Monitor personal resistance levels Improves Disease Management Leumeta™ CellSearch Hepascore™ Improving Patient Care …..Reducing Medical Costs Patients | Growth | People
  • 13. Unparalleled Assets and Capabilities Serving 50% of US Hospitals & Physicians 2,300 Patient Service Centers and Laboratories 900 MD’s and PhD’s 8,500 Phlebotomists & 5,000 Paramedical professionals 3,500 Courier Vehicles and 25 Airplanes - making 90,000 stops each day >140,000 Physician users of Care360 POC testing in >100 Countries Testing ~1,000,000 Patients a Day through our Labs and POC Devices Patients | Growth | People
  • 14. Expanding Diagnostic Scope Near Patient Testing Opportunity to Improve Patient Care Attractive benefits for hospitals, physician offices, rural and international markets Enables more timely and effective decisions Expanding product menu Platform technology Results integrated into Care360 Reducing Medical Costs Patients | Growth | People
  • 15. Expanding Geographic Reach Broadening Our Geographical Coverage Clear leadership in U.S….with room to grow Leverage existing labs in Puerto Rico, Mexico, and UK Providing cervical cancer screening for Ireland NHS Increase foreign testing sent to Nichols Institute Entered India – serving multiple markets Increasing Market Opportunity Patients | Growth | People
  • 16. On Track to Reduce Costs by $500 Million Leverage Lean Six Sigma to Improve Efficiency Streamline Lab Operations Optimize Logistics Routes and PSC Resources Improve Billing and Call Center Operations Leverage Purchasing Capabilities $300 million savings run rate exiting 2008 Maintain Service Levels & Stimulate Growth Patients | Growth | People
  • 17. 2008 Results Strong Growth in Revenue, Earnings and Cash Flow $7.2 B, ↑ 8.1% Revenues 16.9%, ↑ 0.6% Operating Income ↑14% EPS $3.23, Cash from Operations $1.1 Billion Patients | Growth | People
  • 18. 2009 Guidance Continued Revenue & Earnings Growth ↑ ~3% Revenues Operating Income % approaching 18% $3.50 - $3.70, ↑ 8% - 15% EPS Cash from Operations * ~$1 billion CapEx ~$200 million Strenghening our Leadership Position *Excludes expected payment of the $316 million reserve Patients | Growth | People established for the previously disclosed NID matter
  • 19. Building on Strength Leader in a vital and growing industry Uniquely positioned with unparalleled assets & capabilities History of disciplined growth and successful acquisitions Strong cash generator, with a strong balance sheet Proven management team Focused on Execution Patients | Growth | People
  • 20. Patients | Growth | People